Consistent with the results shown in this study, the treatment of MSC itself has been demonstrated to exert protective or therapeutic efficacy against various immune disorders including IBD through the production of immunoregulatory paracrine factors including prostaglandin E2, indoleamine 2,3-dioxygenase-1, and transforming growth factor β1 [28,29]. Here, IDO1 is linked to inflammatory bowel disease.